文献速递哮喘

度普利尤单抗治疗儿童哮喘的长期安全性与有效性评估(LIBERTY ASTHMA EXCURSION)

Assessment of long-term safety and efficacy of dupilumab in children with asthma (LIBERTY ASTHMA EXCURSION): an open-label extension study.
PubMed 文献 · Lancet Respir Med · 2023-11-10

EXCURSION 是一项在 17 个国家 70 个中心开展的 52 周开放标签扩展研究,纳入 365 例既往参加 VOYAGE 研究的中重度哮喘儿童(6–11 岁)。度普利尤单抗继续治疗组(dupilumab/dupilumab)240 例,安慰剂转度普利尤单抗组(placebo/dupilumab)125 例;总体人群中 232 例(63·6%)出现至少一次治疗期间不良事件,安全性特征与母研究 VOYAGE 一致,长期治疗耐受性良好。

要点

  • 52 周开放标签扩展研究中,度普利尤单抗长期安全性特征与 VOYAGE 母研究一致。
  • 总体人群 232/365 例(63·6%)报告至少一次治疗期间不良事件。
  • 最常见不良事件为鼻咽炎、咽炎和上呼吸道感染。

核心结论

  • 在 EXCURSION 研究中,度普利尤单抗长期治疗耐受性良好,安全性特征可接受。

研究设计与样本

  • EXCURSION 为 52 周开放标签扩展研究,在 17 个国家 70 个中心开展。
  • 365 例既往参加 VOYAGE 研究的 6–11 岁中重度哮喘儿童入组,其中 240 例继续度普利尤单抗治疗、125 例由安慰剂转为度普利尤单抗。
  • 度普利尤单抗按体重给药:体重≤30 kg 者 100 mg、体重>30 kg 者 200 mg,每 2 周皮下注射一次。
  • 方案修订后,部分体重≤30 kg 儿童改为 300 mg 每 4 周一次。
  • 主要终点为 52 周研究期间总体人群出现任何治疗期间不良事件的患者数量与比例,统计分析为描述性。

主要发现

  • 总体人群中 232/365 例(63·6%)出现至少一次治疗期间不良事件。
  • dupilumab/dupilumab 组 147/240 例(61·3%)出现治疗期间不良事件。
  • placebo/dupilumab 组 85/125 例(68·0%)出现治疗期间不良事件。
  • 最常见治疗期间不良事件为鼻咽炎、咽炎和上呼吸道感染。

临床怎么用

  • 对于 6–11 岁中重度哮喘儿童,度普利尤单抗长期治疗的安全性数据可支持临床用药参考,具体用药需结合体重与方案要求。

局限性

  • 本研究为开放标签扩展研究,统计分析为描述性,未设安慰剂对照。
  • 安全性结论来自单一人群与特定给药方案,部分剂量在方案修订后调整。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Dupilumab efficacy and safety in children aged 6-11 years with uncontrolled, moderate-to-severe asthma were shown in the VOYAGE study-a 52-week, multinational, multicentre, phase 3 randomised, double-blind, placebo-controlled trial. We aimed to evaluate the long-term safety and efficacy of dupilumab in children with moderate-to-severe asthma who previously participated in the VOYAGE study. METHODS: 365 of 408 children with moderate-to-severe asthma from VOYAGE enrolled in EXCURSION, a 52 week, open-label extension study conducted at 70 centres across 17 countries. 240 children continued with add-on dupilumab (dosed according to bodyweight: 100 mg for those weighing ≤30 kg and 200 mg for those weighing more than 30 kg at EXCURSION baseline) once every 2 weeks administered by subcutaneous injection (dupilumab/dupilumab group) and 125 children on placebo during VOYAGE initiated dupilumab (100 or 200 mg, according to bodyweight), once every 2 weeks administered by subcutaneous injection (placebo/dupilumab group). Following a protocol amendment, for a subset of children weighing 30 kg or less, the dose was changed to 300 mg once every 4 weeks. The primary endpoint for the open-label extension study was the number and proportion of patients with any treatment-emergent adverse event (TEAE) during the 52-week study period in the overall population (defined as children aged 6-11 years old with moderate-to-severe asthma who previously completed VOYAGE). Statistical analyses were descriptive. This study is registered with ClinicalTrials.gov (NCT03560466; EXCURSION). FINDINGS: Children who completed VOYAGE were eligible to enrol in EXCURSION between June 21, 2018 and Aug 18, 2020. During EXCURSION, the safety profile and proportion of patients reporting TEAEs were consistent with those observed during the parent study (VOYAGE). In the overall population, 232 (63·6%) of 365 patients experienced at least one TEAE (dupilumab/dupilumab: 147 [61·3%]; placebo/dupilumab: 85 [68·0%]). The most frequently reported TEAEs were nasopharyngitis, pharyngitis, and upper respiratory tract infections. INTERPRETATION: In EXCURSION, long-term treatment with dupilumab was well tolerated with an acceptable safety profile. FUNDING: Sanofi and Regeneron Pharmaceuticals.

来源:Lancet Respir Med,查看原文。版权归原作者所有。

引用

  1. Bacharier LB, Maspero JF, Katelaris CH, et al. Assessment of long-term safety and efficacy of dupilumab in children with asthma (LIBERTY ASTHMA EXCURSION): an open-label extension study. Lancet Respir Med. 2023. PMID: 37956679. doi:10.1016/S2213-2600(23)00303-X

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。